Home > Boards > US OTC > Biotechs >

Galectin Therapeutics Inc. (GALT)

Add GALT Price Alert      Hide Sticky   Hide Intro
Search This Board: 
Last Post: 4/16/2018 9:56:57 AM - Followers: 77 - Board type: Free - Posts Today: 0

Galectin Therapeutics is a biotechnology company focused on discovery and development. We apply our leadership in galectin science and drug development to create new therapies for fibrotic disease and cancer. Drug candidates based on our unique carbohydrate technology target galectin proteins, which are key mediators of biologic and pathologic function.

Galectin Therapeutics is pursuing therapies for indications in which galectins have a demonstrated role in the pathogenesis of a particular disease. We focus on diseases with serious, life-threatening consequences to patients, and those where current treatment options are limited. Our strategy is to establish clinical development approaches that add value to the Company in the shortest time possible, and to seek partners as the program advances and requires much greater resources.

Galectin Therapeutics leverages extensive scientific and development expertise as well as established relationships with outside sources to achieve cost effective and efficient development. We are pursuing a clear development pathway to clinical enhancement and commercialization for our lead compounds in liver fibrosis and cancer immunotherapy.

Galectin Therapeutics is pursuing therapies for indications in which galectins have a demonstrated role in the pathogenesis of a particular disease. We focus on diseases with serious, life-threatening consequences to patients, and those where current treatment options are limited. Though we do not have any current marketed products, our research and development programs, designed to ultimately help patients and their physicians, are focused on:




Fibrosis is the development of excess fibrous connective tissue in an organ when exposed to a chronic disease. The longer the disease affects the organ, the more fibrous tissue is deposited and this ultimately results in the failure of the organ. Galectin Therapeutics’ drug candidates provide a promising and exciting new approach for the treatment of fibrotic diseases, including liver, lung and kidney fibrosis. Significant unmet need exists for treatment options in fibrosis. For example, there are currently no approved medical treatments available for the millions of patients in the U.S. who have non-alcoholic steatohepatitis with advanced fibrosis – commonly known as fatty liver disease. Learn about fibrosis and our research in this area including galectin effects on liver fibrosis, lung fibrosis and kidney fibrosis.




Cancer harms the body when damaged cells divide uncontrollably to form lumps or masses of tissue called tumors. Research shows the potential for galectin inhibition to play an important role in cancer therapy, particularly tumor immunotherapy – an emerging treatment that enhances the activity of the immune system against cancer cells. There are more than 100 types of cancers, and for many of these cancers, few treatment options exist. Our drug candidates provide a new and complimentary approach to other drugs on the market for the treatment of cancer. Learn more about cancer and immunotherapy.


Current Price
Bid Ask Day's Range
  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
GALT News: Statement of Changes in Beneficial Ownership (4) 04/18/2018 04:32:56 PM
GALT News: Galectin Therapeutics to Present at 2nd Annual NASH Summit 2018 04/18/2018 08:00:00 AM
GALT News: Galectin Therapeutics Late-Breaker Presentation at The International Liver Congress Reinforces and Extends the Positive Effec... 04/16/2018 08:00:00 AM
GALT News: Current Report Filing (8-k) 04/16/2018 07:52:46 AM
GALT News: Proxy Statement (definitive) (def 14a) 04/11/2018 04:03:34 PM
News News Alert: Statement of Changes in Beneficial Ownership (4) 04/18/2018 04:32:56 PM
PlusOneCoin Top Posts
No plusone'd posts yet. Be the first!
#3312   I was glad to see that in the thefamilyman 04/16/18 09:56:56 AM
#3311   New data presented at EASL presents valid reason biotech2010 04/16/18 08:24:37 AM
#3310   Thank you - not much new info but Amatuer17 04/15/18 10:23:30 PM
#3309   Galectin-3 inhibitor improves hepatic ballooning in NASH This is sokol 04/15/18 09:24:57 PM
#3308   Was wrong BTD timeline - it is 60 Amatuer17 04/15/18 07:59:11 AM
#3307   Did you find the late breaking poster? Was there Amatuer17 04/15/18 07:52:08 AM
#3306   It is not about money - NASH is Amatuer17 04/14/18 01:53:19 PM
#3305   Because GALT would never go bankrupt. At Vector93 04/13/18 10:03:06 AM
#3304   As I remember, Richard Uihlein’s $10 million loan sokol 04/12/18 09:02:16 PM
#3303   Richard Uihlein isn’t going to let the company jmh0602 04/12/18 07:44:28 PM
#3302   I'm wondering why there will be a partnership IRAHopeful 04/12/18 04:16:49 PM
#3301   This board is so quiet right before two jimmy667 04/08/18 02:36:19 PM
#3300   AS increase doesn’t have to mean dilution. Vector93 04/02/18 01:51:22 PM
#3299   Dilution INTL 04/02/18 09:15:55 AM
#3298   * * $GALT Video Chart 03-29-18 * * ClayTrader 03/29/18 05:20:54 PM
#3297   Breakthrough Drug application submitted. Meeting with the Vector93 03/12/18 08:07:46 PM
#3296   He is talking about Ketruda Check this - http://investor.galectintherapeutics.c Amatuer17 03/10/18 09:39:05 AM
#3295   It doesn't work with Yervoy Coolec78 03/09/18 06:51:38 AM
#3294   He is focused on the upcoming cohort 3 Amatuer17 03/08/18 05:54:48 PM
#3293   Hod chase is on europtiger 03/08/18 11:27:38 AM
#3292   There was a seeking alpha article by Mike jmh0602 03/08/18 10:24:44 AM
#3291   News??? that would make this difference? All IRAHopeful 03/08/18 09:50:29 AM
#3290   Here we Go europtiger 03/08/18 09:33:40 AM
#3289   Soon 52 week hat geh Break here europtiger 03/08/18 08:42:14 AM
#3288   News out europtiger 03/08/18 08:41:22 AM
#3287   This is 3 month old article so not Amatuer17 03/07/18 06:10:21 PM
#3286   Hear u This is still an amazing buy mjw007 01/17/18 12:17:31 PM
#3285   Crazy day...traders dream Selett 01/16/18 03:21:37 PM
#3284   Don't forget to mention Dr. Gil Omenn MD. rickyricks 01/15/18 12:12:48 PM
#3283   Two quotes from Dr Scott Friedman about trial biotech2010 01/14/18 07:51:17 PM
#3282   Nash only? Darwinian 01/11/18 11:01:49 PM
#3281   Conceptually, galectin has a job to do, if PeterKarol 01/10/18 08:46:22 PM
#3280   Hope you are right !! This company is a mjw007 01/08/18 03:29:53 PM
#3279   Such a Beauty europtiger 01/08/18 03:00:49 PM
#3278   Pfizer P1 Nash, Novartis, Gilead, BMY, ICPT. rickyricks 01/07/18 12:27:46 PM
#3277   San Francisco, CA is in the Presentation Title Tesla1 01/06/18 07:16:06 PM
#3276   The only smart thing you’ve said is “you KnokKnok 01/05/18 11:58:55 AM
#3275   It's interesting about the 2 mg dosage. I Darwinian 01/05/18 08:26:42 AM
#3274   I didn't 'turn on a dime', I said biotech2010 01/05/18 06:08:19 AM
#3273   you bought shares! Wow - that's equivalent Chess Master 01/05/18 02:39:28 AM
#3272   FWIW at this point, I came across this Darwinian 01/04/18 06:21:12 PM
#3271   What badders me why smaller dose works much Coolec78 01/04/18 05:25:07 PM
#3270 Th biotech2010 01/04/18 04:46:24 PM
#3269   The new 8K filing is supposedly for a thefamilyman 01/04/18 12:22:40 PM
#3268   You n me both... thefamilyman 01/03/18 12:01:04 AM
#3267   After all this time and effort, I hope Darwinian 01/02/18 11:00:18 PM
#3266   Thanks for posting This stock is a steal mjw007 12/29/17 02:44:57 PM
#3265   Nice! Maybe those January Call Options will thefamilyman 12/29/17 11:04:09 AM
#3264   Another article on GALT and Short FAKE news Chess Master 12/29/17 09:53:13 AM
#3263   It is now inhumane to knowingly give a rickyricks 12/24/17 06:51:48 PM